CAJ | 학술논문

目的：研究玻璃体腔注射贝伐单抗Avastin后增生性糖尿病视网膜病变（ PDR）患者血清中血管内皮细胞生长因子（ VEGF）的变化。方法收集玻璃体腔注射Avastin后PDR患者血清样本（注射前当天，注射后1 d，注射后7 d，注射后28 d），并以注射前当天的血清样本为基准值作为对照，用ELISA 方法测定血清中VEGF的含量。结果玻璃体腔注射Avastin术后，所有样本血清中VEGF含量都降低，降低幅度在术后7 d达到最大峰值，术后28 d VEGF有所上升，但仍未达到术前水平。结论一次玻璃体腔注射Avastin术后，血清中VEGF含量降低并且维持相当时间，说明Avastin进入到血液循环中，因此有必要密切关注Avastin玻璃体腔注射后的系统性影响和对未注射眼的影响。
목적：연구파리체강주사패벌단항Avastin후증생성당뇨병시망막병변（ PDR）환자혈청중혈관내피세포생장인자（ VEGF）적변화。방법수집파리체강주사Avastin후PDR환자혈청양본（주사전당천，주사후1 d，주사후7 d，주사후28 d），병이주사전당천적혈청양본위기준치작위대조，용ELISA 방법측정혈청중VEGF적함량。결과파리체강주사Avastin술후，소유양본혈청중VEGF함량도강저，강저폭도재술후7 d체도최대봉치，술후28 d VEGF유소상승，단잉미체도술전수평。결론일차파리체강주사Avastin술후，혈청중VEGF함량강저병차유지상당시간，설명Avastin진입도혈액순배중，인차유필요밀절관주Avastin파리체강주사후적계통성영향화대미주사안적영향。
Objective Avastin (bevacizumab) intravitreal injections are widely used in the treatment of diabeticretinopathy.This study was to determine the serum concentrations of vascular endothelial growth factor (VEGF) in patientswith diabetic retinopathy after intravitreal injection of bevacizumab .Methods Twenty-two patients (22 eyes) diagnosedwith active proliferative diabetic retinopathy were enrolled in this study .Bevacizumab 1.25 mg was administered intravitrealy.Serum VEGF concentration was measured by ELISA on the day of the bevacizumab administration and on day 1, day7, and day 28.Results Twenty-four hours after bevacizumab administration, serum VEGF concentration significantly decreasedfrom baseline in all patients, and reached a nadir at the 7th day.VEGF level rose again at 28 days after the treatmentbut did not reached pre-treatment level in most of patients.Conclusion Decreased serum VEGF level after single intravitrealinjection of bevacizumab indicated that bevacizumab entered the circulation and maintained a therapeutic level fora long time.Therefore, physicians should be cautious about systemic side effects and side effects in the fellow eye .